Vinorelbinum [Latin] en es it fr

Vinorelbinum [Latin] Brand names, Vinorelbinum [Latin] Analogs

Vinorelbinum [Latin] Brand Names Mixture

  • No information avaliable

Vinorelbinum [Latin] Chemical_Formula


Vinorelbinum [Latin] RX_link

Vinorelbinum [Latin] fda sheet

Vinorelbinum [Latin] msds (material safety sheet)

Vinorelbinum [Latin] Synthesis Reference

No information avaliable

Vinorelbinum [Latin] Molecular Weight

778.932 g/mol

Vinorelbinum [Latin] Melting Point

No information avaliable

Vinorelbinum [Latin] H2O Solubility

No information avaliable

Vinorelbinum [Latin] State


Vinorelbinum [Latin] LogP


Vinorelbinum [Latin] Dosage Forms


Vinorelbinum [Latin] Indication

For the treatment of non-small-cell lung carcinoma

Vinorelbinum [Latin] Pharmacology

Vinorelbine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinorelbine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vinorelbine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

Vinorelbinum [Latin] Absorption

No information avaliable

Vinorelbinum [Latin] side effects and Toxicity

No information avaliable

Vinorelbinum [Latin] Patient Information

No information avaliable

Vinorelbinum [Latin] Organisms Affected

Humans and other mammals